Frontotemporal Disorders Treatment Market Size is contemplated to experience remarkable growth-fueling trends from 2022 to 2028.
The prevalence of frontotemporal disorders (FTD) and associated diseases like dementia will be the primary factor contributing to the industry growth over the projected timeframe. As per the U.S. Department of Health and Human Service, unlike other forms of dementia, frontotemporal disorders tend to occur at a comparatively younger age, and about 60% of patients are 45-64 years old. Furthermore, increasing grants for frontotemporal drug development and emerging funding by non-government organizations will boost the industry forecast in the upcoming years.
A rapid upsurge in the geriatric population and growing R&D activities, are likely to contribute to the expansion of the frontotemporal disorders treatment market in the future. Moreover, rising life expectancy and increasing cases of head injuries may also push the demand for frontotemporal disorders treatment in the upcoming years. As per a study published in Neurology in 2020, the risk of dementia is nearly 2-3 times higher in people with traumatic brain injuries.
With respect to the disease segment, behavioral variant frontotemporal dementia may gain considerable proceeds, driven by the emerging requirement for better care and supervision for patients suffering from this disorder. It is considered the most common form of FTD and can impact the behavior, personality, and judgment of an individual. Patients with bvFTD can face difficulty in cognition, sequencing, planning, prioritizing, and repeating activities, movement, and communication. Other symptoms include overeating, repetitive compulsive and inappropriate behavior, lack of personal hygiene, and inhibition.
The antidepressants segment in the frontotemporal disorders treatment market may witness lucrative growth opportunities during the analysis timeframe due to their ability to control cortisol levels and behavioral symptoms like depression, social anxiety, dysthymia associated with frontotemporal disorders. In addition, R&D activities and new product innovations will further support segment expansion.
Hospitals may emerge as a major end-use segment for frontotemporal disorders treatment in the forthcoming years owing to the rising demand for comprehensive diagnosis, monitoring, treatment, and supervision by specialized and certified medical professionals in these settings.
North America frontotemporal disorders treatment market may register decent progression in the coming years due to improved health infrastructure and increasing cases of dementia and other disorders in the region. Growing awareness towards the target disease and favorable reimbursement policies will further propel the industry outlook in the foreseeable future.
Some of the prominent industry players include AstraZeneca, Allergan, Eli Lilly, Johnson & Johnson, GlaxoSmithKline, Merck, Sanofi, Mylan, and Pfizer. These players are adopting several strategies like collaborations, partnerships, mergers, and acquisitions to safeguard their market position and support the industry growth in the years ahead. In December 2021, Eli Lilly entered into a partnership with Verge Genomics by joining a $98 million funding for drug development for neurodegenerative disorders.
Like many other industries that were hard hit by the pandemic last year, the frontotemporal disorders treatment industry was no exception. An emerging number of COVID-positive cases leading to mortality and morbidity all across the globe led to growing infection anxiety among people from all age groups. In addition, travel and movement restrictions, social distancing norms, and reservation of hospital beds for COVID patients limited the clinical and hospital visits.
However, the introduction of virtual healthcare consultation and remote patient monitoring coupled with the increasing COVID-19 vaccinations and end of lockdown restrictions will help the market recover shortly and register considerable growth in the upcoming years.
Market, By Disease Type
Market, By Drug Class
Market, By End-use
The above information is provided for the following regions and countries: